司太立 (603520)

Zhejiang Starry Pharmaceutical Co., Ltd.

ASH

Tags

Specialized-Sophisticated-Distinctive-Innovative EnterprisesPharmaceutical ManufacturingPharmaceuticals and HealthcareYesterday's OutperformersLithium Batteries医药生物Chemical Pharmaceuticals

K-Line Chart

No K-line data available

Company NameZhejiang Sitaile Pharmaceutical Co., Ltd.
Listing Date2016-03-09
Issue Price12.15RMB
Registered Capital43840.988110k RMB
Legal RepresentativeHu Jian
Registered AddressNo. 1 Sitaile Avenue, Modern Industrial Cluster Zone, Xianju County, Zhejiang Province
IndustryChemical Pharmaceuticals
Main BusinessThe company belongs to the chemical pharmaceutical API manufacturing sector within the pharmaceutical manufacturing industry. It specializes in the R&D, production, and sales of active pharmaceutical ingredients (APIs) and intermediates for drugs such as X-ray contrast agents and quinolone antibacterial agents. The company's main X-ray contrast agent products include APIs like Iohexol, Iodixanol, and Iopamidol. Its main quinolone antibacterial products include APIs like Levofloxacin Hydrochloride and Levofloxacin.
Company ProfileZhejiang Sitaile Pharmaceutical Co., Ltd. was founded in 1997. It is a high-tech enterprise specializing in the R&D, production, and sales of X-CT non-ionic contrast agent series and quinolone series APIs and intermediates. It is currently a leading production base for diagnostic drug APIs in China. The company was listed on the Shanghai Stock Exchange on March 9, 2016, with stock code: 603520. Over the past 20+ years, the company has maintained a stable and positive development momentum, becoming a leading domestic producer of X-CT non-ionic contrast agent APIs. Products with industrial-scale production capacity include Iohexol API, Iopamidol API, Ioversol API, Iopromide API, Iodixanol API, etc. Among these, the production capacity and output of Iohexol API rank first in China. The company's product quality is stable and has obtained certifications from multiple developed countries. Currently, there are only four global manufacturers of Iohexol API holding a European CEP certificate, and Sitaile is the sole Chinese company among them. There are also four global Iohexol API manufacturers holding Japanese registration certificates, and Sitaile is one of them.

Stock Details

1. Key Indicators

  • Total Shares(W): 43840.99
  • Circulating A-Shares(W): 43840.99
  • Earnings Per Share(RMB): 0.0700
  • Net Assets Per Share(RMB): 5.9315
  • Operating Revenue(W RMB): 184501.57
  • Total Profit(W RMB): 3783.79
  • **Net Profit Attributable to Parent(W RMB) **: 2882.48
  • Net Profit Growth Rate(%): 221.14
  • Weighted Return on Equity(%): 1.1000
  • Operating Cash Flow Per Share(RMB): 0.3110
  • Undistributed Profit Per Share(RMB): 0.7987
  • Capital Reserve Per Share(RMB): 3.7478

2. Main Business

The main business covers:

  • Research, development, production, and sales of non-ionic iodine contrast agents
  • Research, development, production, and sales of quinolone antibacterial drugs
  • Research, development, production, and sales of pharmaceutical raw materials and intermediates

3. Company Basic Information

  • Company Name: Zhejiang Starry Pharmaceutical Co., Ltd.
  • Listing Date: 2016-03-09
  • Industry: Pharmaceutical Manufacturing
  • Address: No. 1 Starry Avenue, Modern Industrial Agglomeration Zone, Xianju County, Zhejiang Province, China
  • Website: https://www.starrypharm.com/
  • Company Profile: On January 25, 2011, based on the resolution of the board of directors of Starry Limited and the approval obtained from the Zhejiang Provincial Department of Commerce on February 25, 2011 (Zhe Shang Wai Zi Han [2011] No. 67), Starry Limited was transformed into a joint stock company. Using the audited net assets of RMB 225,674,281.41 as of December 31, 2010 as the basis, and at a ratio of 2.5075:1, it was converted into 90 million shares. Tianjian Certified Public Accountants reviewed the registered capital at the time of the company's establishment and issued the "Capital Verification Report" (Tianjian Yan [2011] No. 56). On March 9, 2011, the industrial and commercial change registration procedures for the company's establishment were completed at the Taizhou Administration for Industry and Commerce, and the "Business License of Enterprise Legal Person" with registration number 331000400001749 was obtained.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Invesco Great Wall Business Model Preferred Hybrid Securities Investment Fund (LOF) Class A Fund 1061.58 2.42
2 Shanghai Muxin Private Fund Management Co., Ltd. - Muxin Chunchen No. 1 Private Securities Investment Fund Private Securities Investment Fund 654.91 1.49
3 Invesco Great Wall New Horizon Flexible Allocation Regular Open Hybrid Initiated Securities Investment Fund Fund 605.21 1.38
4 Penghua Pharmaceutical Technology Equity Securities Investment Fund Class A Fund 461.63 1.05
5 China Resources Shenzhen International Trust Co., Ltd. - China Resources Trust · Shenzhi Assets Xingzhi Collective Fund Trust Plan General Legal Person 385.84 0.88
6 Huashang Quality Value Hybrid Securities Investment Fund Class A Fund 363.27 0.83
7 Changsha Lugu Capital Management Co., Ltd. General Legal Person 358.97 0.82
8 Galaxy Pharmaceutical Health Hybrid Securities Investment Fund Class A Fund 335.08 0.76
9 Huashang Le Xiang Hu Lian Flexible Allocation Hybrid Securities Investment Fund Class A Fund 314.87 0.72
10 Industrial Health Care Hybrid Securities Investment Fund Class A Fund 150.28 0.34

5. Concept Sectors

  • Lithium Battery
  • Specialized, Refined, Distinctive, and Innovative (SRDI)

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information